Compare BOTJ & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | KLRS |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 116.8M |
| IPO Year | 2015 | N/A |
| Metric | BOTJ | KLRS |
|---|---|---|
| Price | $22.85 | $4.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 11.0K | ★ 82.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 13.71 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.62 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $13.03 | $2.14 |
| 52 Week High | $23.71 | $11.88 |
| Indicator | BOTJ | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 40.90 |
| Support Level | $20.18 | $4.35 |
| Resistance Level | $23.71 | $5.38 |
| Average True Range (ATR) | 0.41 | 0.37 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 24.56 | 38.18 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.